Anbio Biotechnology (NASDAQ:NNNN) Shares Down 7.8% – Here’s Why

Anbio Biotechnology (NASDAQ:NNNN) shares dropped 7.8% on Monday . The stock traded as low as $34.65 and last traded at $31.7410. Approximately 190 shares traded hands during trading, a decline of 100% from the average daily volume of 44,076 shares. The stock had previously closed at $34.44.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of “Hold”.

Anbio Biotechnology Stock Performance

The stock has a fifty day simple moving average of $27.42.

Anbio Biotechnology (NASDAQ:NNNN) last posted its quarterly earnings results on Tuesday, April 7th. The company reported $0.03 EPS for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.